ALTHOUGH many long-acting coronary vasodilators have been introduced for the prophylactic treatment of angina pectoris few have survived a controlled objective study in which the main criterion of effectiveness is an improvement in the degree of myocardial ischoemia and not solely an alteration in the frequency or severity of anginal attacks.
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A new coronary vasodilator, benziodarone (Cardivix), a benzfuran derivative, has been found experimentally to produce a marked increase in coronary blood flow in healthy dogs (Charlier, 1959) , and has also been claimed to produce considerable improvement clinically in anginal patients (Gillott, I959 ). Gillott's study was based on an uncontrolled and subjective evaluation of the action of benziodarone. Assessment of any anti-anginal drug, however, must take into consideration the suggestibility of anginal patients, the limitations of subjective data provided by the patients themselves, and the lack of any direct relationship between the development and severity of anginal pain and the degree of coronary insufficiency (Russek, Zohman and Dorset, 1955) .
It is with these considerations in mind that it was decided to carry out a controlled doubleblind and objective evaluation of the use of benziodarone in the treatment of angina pectoris.
Patients and Methods
Twelve patients, aged from 4I to 67 years, with typical angina pectoris on exertion were studied. All the patients were males but this was not due to sex selection as suitable patients were included in the trial as -they became available. The duration of angina ranged from 6 months to 4 years. The presumptive cause of the angina was coronary artery disease and 2 patients had electrocardiographic evidence of -previous myocardial infarction. All Fig. I ). The position of V5 is marked on the patient's chest before exercise so that it can be accurately replaced after exercise. Depression of the ST segment below the iso-electric line, either plane or sagging, of at least o.o8 second's duration is regarded as indicative of myocardial ischmmia (LloydThomas, I96I; Master and Rosenfeld, I96I); the degree and duration of depression are recorded for each patient. All 12 patients in the study developed ischxmic changes after exercise. The nature and purpose of the tests were explained to all patients.
The weight and resting blood pressure were also recorded monthly in all patients and any side-effects with the drugs noted.
Results
Since the patients were acting as their own controls, in addition to comparison of mean values in the various periods of study, the differences in each individual patient resulting from benziodarone or placebo were analysed statistically. In this way, variation between different subjects was eliminated and the changes produced by the drugs became more apparent. Table 2 .
When using benziodarone neither the mean amount of exercise carried out before angina occurred, nor its rate of performance differed significantly from the control values. In addition there was no significant change in these parameters following use of the drug.
The degree of depression of the ST segment after exercise and the time required for it to return to the iso-electric line is shown in Table 3 . There was no significant reduction in either the mean amount of ST depression or its duration after a course of benziodarone. Similarly the change in degree and duration of ST depression with benziodarone was not a significant one.
Finally, the duration of angina induced by the exercise tolerance tests is recorded in Table 4 , and once more benziodarone failed to influence significantly either the mean duration of angina or the mean change in its duration. There was no alteration in either blood pressure or weight in the I2 patients during the course of the investigation.
The only untoward side-effect experienced with benziodarone was gastro-intestinal discomfort which occurred in two patients soon after taking each dose.
Discussion
It has been suggested that the only way to determine the clinical usefulness of an anti-anginal drug is to test its ability to relieve angina (Katz, I956) . However, there are a number of difficulties inherent in .this approach. First is the suggestibility of anginal patients and the frequency of response to any new preparation irrespective of its active or inert properties (Greiner and coworkers, I950). To some extent this can be overcome by using a placebo but here also relief of angina occurs in as many as 40% of patients (Evans and Hoyle, I933 of an interested, biased and untrained assistant.
In addition there are a number of drugs which may relieve anginal pain such as analgesics, placebos and coronary vaso-dilators. While the patient's concern is with the relief of the pain, it is the physician's responsibility to control this by a drug which eliminates the pain-producing myocardial anoxia and not by measures which interfere with either the anatomical pathways of pain sensation or its central perception. A drug which improves angina without producing a corresponding improvement in myocardial blood supply may result in increased myocardial ischaemia by allowing excessive exertion (Sandler, I96I) . Finally the lack of any direct relationship between the development and severity of anginal pain and the degree of coronary insufficiency (Russek, Zohman and Dorset, 1955) Gillott (1959) reported considerable improvement with benziodarone in 77% of i8o anginal patiehts but since assessment was mainly subjective and entirely uncontrolled the value of these observations is dubious. Similar criticism applies to studies carried out by Vercruyssen and Geyssens (1962) and Dailheu-Geoffroy and Nataf (I96I).
The present study showed that benziodarone twas no better than a placebo in reducing the frequency of anginal attacks and in addition no objective improvement either in exercise tolerance or myocardial ischaemia resulted from its use.
Summary
A controlled double-blind and objective evaluation of benziodarone (Cardivix), a new coronary vasodilator, in the prophylactic treatment of angina pectoris has been carried out in i 2 patients.
The drug failed significantly to influence either the frequency of anginal attacks or exercise tolerance and the resulting electro-cardiographic changes of myocardial ischeemia.
